艾伯维提交白癜风新药申请，2025年营收突破600亿美元

Group 1 - AbbVie submitted a new indication application for Upadacitinib to treat adult and adolescent non-segmental vitiligo to the FDA and EMA, potentially making it the first systemic drug for vitiligo globally [1] - AbbVie's total revenue for 2025 reached $61.16 billion, marking an 8.6% year-over-year increase, officially entering the $60 billion club [1] - Global sales of Upadacitinib amounted to $8.30 billion, reflecting a 39.1% year-over-year growth, while sales of Risankizumab reached $17.56 billion, up 49.9% [1] Group 2 - AbbVie's stock price fluctuated between $225.82 (highest on February 6) and $214.04 (lowest on February 5) during the week of February 5 to February 12, with a closing price of $223.19 on February 12, up 1.04% [2] - The pharmaceutical sector rose by 0.83% during the same period, while the Dow Jones index increased by 0.50% [2] Group 3 - AbbVie's immunology business generated $30.4 billion in revenue, a 14% year-over-year increase, becoming the core growth driver [3] - The neuroscience business has upgraded to a core pillar, with Vraylar generating $3.62 billion and Botox in the migraine field generating $3.77 billion [3] - The company acquired Capstan to gain access to the tLNP platform, positioning itself in the cutting-edge CAR-T therapy field [3] Group 4 - On February 5, multiple Wall Street firms updated their ratings, with TD Cowen maintaining a buy rating and a target price of $280, while Evercore lowered its target price to $228, and UBS maintained a hold rating with a target price of $230 [4] - Analysts are focusing on the company's pipeline progress and the potential for upward revisions in earnings guidance [4]